TGFB1 and prostate carcinoma: To overcome the excess TGF-β in the TME, Kloss et al. blocked TGF-β signaling by co-expressing a dominant-negative TGF-β receptor II (TGF-βRII) in PSMA CAR T cells targeting prostate cancer.